Form 4: Neurocrine Biosciences Chief Medical Officer Reports Stock Transactions
SEC Form 4 Filing
Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.
Summary
- Eiry Roberts, the Chief Medical Officer of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership.
- On February 8, 2025, 1,860 shares vested from a Restricted Stock Unit (RSU) granted on February 8, 2021.
- These shares vested according to the terms of the RSU, with previous vestings occurring on February 8th of 2022, 2023, and 2024.
- On February 10, 2025, Dr. Roberts sold 980 shares of common stock at a weighted average price of $118.217 per share, with prices ranging from $116.07 to $123.53.
- The sale was executed under a Rule 10b5-1 trading plan adopted on June 10, 2021.
- Following these transactions, Dr. Roberts beneficially owns 33,253 shares of Neurocrine Biosciences stock, with 32,068 of those shares held in The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and do not necessarily reflect a change in the insider's outlook on the company.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors to gauge management's sentiment and potential future performance.
Stakeholder Impact
- The stock sale could have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small volume of shares sold.
Key Dates
| Date | Description |
|---|---|
| June 10, 2021 | Date of adoption of Rule 10b5-1 trading plan |
| February 8, 2021 | Date the Restricted Stock Unit was granted |
| February 8, 2022 | First vesting date of the RSU (1,859 shares) |
| February 8, 2023 | Second vesting date of the RSU (1,860 shares) |
| February 8, 2024 | Third vesting date of the RSU (1,860 shares) |
| February 8, 2025 | Fourth vesting date of the RSU (1,860 shares) |
| February 10, 2025 | Date of stock sale |
| February 12, 2025 | Date of Form 4 filing |
Keywords
Form 4, Neurocrine Biosciences, NBIX, Eiry Roberts, Chief Medical Officer, Stock Sale, Restricted Stock Unit, 10b5-1 Trading Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.